Max Healthcare Institute Ltd Allots 3,048 Equity Shares Under Employee Stock Option Scheme 2022
The Nomination & Remuneration Committee (NRC) of Max Healthcare Institute Limited approved the allotment of equity shares, marking an increase in the company's paid-up capital. The approval was granted during a committee meeting held on August 13, 2026, confirming the exercise of vested stock options under the Max Healthcare Institute Limited - Employee Stock Option Scheme 2022.The allotment involved 3,048 equity shares, each having a face value of ₹10 and being fully paid up.
Following the issuance, the paid-up equity share capital of the Company saw an increase. The updated figures are detailed in the following table:
| Particulars | Pre-allotment | Post-allotment |
|---|---|---|
| No. of Equity Shares | 97,32,73,438 | 97,32,76,486 |
| Face Value (₹) | 10 | 10 |
| Paid-up Equity Capital (₹) | 973,27,34,380 | 973,27,64,860 |
Details of Share Allotment
The details concerning the allotment of equity shares under the Employee Stock Option Scheme 2022 were finalized on August 13, 2026. Key transaction metrics for this issue include:| Detail | Value |
|---|---|
| Scheme Title | Max Healthcare Institute Limited - Employee Stock Option Scheme 2022 |
| Date of Allotment | August 13, 2026 |
| Number of Shares Allotted | 3,048 equity shares |
| Par Value per Share | ₹ 10 |
| Exercise Price per Share | ₹ 350 |
| Premium per Share | ₹ 340 |
| Total Issued Shares after this Issue | 97,32,76,486 equity shares |
The company's registered office is located at 401, 4th Floor, Man Excellenza, S. V. Road, Vile Parle (West), Mumbai - 400 056, Maharashtra. The shares are listed on the BSE and the National Stock Exchange of India Limited.
MAXHEALTH Stock Price Movement
Shares of Max Healthcare Institute Limited slipped on Wednesday, closing down 3.13% to settle at ₹1007.5 after trading significantly weaker throughout the session. The stock saw a volume of 2.76 million shares, reflecting sustained selling pressure across the day's market activity.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.